Roche gained FDA priority review. Roche Holding stock fell 2.08 percent.

Published on 10/08/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sales reached CHF 30.364 billion in first half, down 2.00 percent. Roche Holding stock costs EUR 378.90 versus EUR 386.94 on October 8, 2026.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding (ISIN CH1499059983) was trading at EUR 378.90 at Lang & Schwarz on October 8, 2026 at 11:51 a.m. CEST, versus the Tradegate close of EUR 386.94, a decline of 2.08 percent. Roche gained priority review for fenebrutinib from the U.S. Food and Drug Administration on September 30, 2026, according to Roche.

Fenebrutinib raises the pipeline stakes

The regulatory filing covers relapsing multiple sclerosis and primary progressive multiple sclerosis. Roche said fenebrutinib reduced annualized relapse rates by 51.10 percent in FENhance 1 and 58.50 percent in FENhance 2 versus teriflunomide over 96 weeks.

The same September 30 release reported a 12.00 percent numerical reduction in progression risk versus Ocrevus in the FENtrepid study. The safety picture is more balanced: serious adverse events were 19.00 percent in both the fenebrutinib and Ocrevus groups in FENtrepid, while the two RMS studies showed rates between 6.00 percent and 11.00 percent across treatment arms.

First-half sales provide the counterweight

Roche's first-half 2026 group sales totaled CHF 30.364 billion, compared with CHF 30.944 billion in the same period a year earlier, a 2.00 percent decline. IFRS operating profit was CHF 9.671 billion, down 1.00 percent year over year, according to VCBeat.

The contrast matters for the stock story. Fenebrutinib offers a quantified late-stage pipeline opportunity, while the first-half figures show that Roche still has to translate development progress into renewed top-line growth.

October 22 is the next test

Roche has scheduled its third-quarter 2026 sales release for October 22, 2026, before the Swiss Stock Exchange opens, with an investor presentation at 2:00 p.m. CEST, according to Roche. That date should give investors a fresh read on commercial momentum before the company reaches the next major regulatory milestones.

Stock trades below the Tradegate close

At Lang & Schwarz, Roche Holding stock was trading at EUR 378.90 on October 8, 2026 at 11:51 a.m. CEST. The price was 2.08 percent below the Tradegate close of EUR 386.94 dated October 7, 2026; this comparison uses the German venue close because the Lang & Schwarz page did not provide a prior close. The further course of trading is shown by the continuously updated real-time quote of Roche Holding stock.